Newsroom



News

PHCentral News is gathered daily to bring you the latest developments in pulmonary hypertension treatments and research as well as stories we think are useful on an array of topics.  Under current news, you will find a dynamic list of stories for the last thirty (30) days.  You will find older news stories in our archives.    Stories about specific treatments can also be found in the medical section.

If you run across a PH news story we've missed or important story with broad appeal, please send us the link and we'll make sure it gets added.   Send news:  contact/info+phcentral+org.



  • March 1, 2015
  • Role for Telomerase in Pulmonary Hypertension
  • (Circulation) Cells exhibiting dysregulated growth may express telomerase reverse transcriptase (TERT), the dual function of which consists of maintaining telomere length, in association with the RNA template molecule TERC, and controlling cell growth. Here, we investigated lung TERT in human and experimental pulmonary hypertension (PH) and its role in controlling pulmonary artery smooth muscle cell (PA-SMC) proliferation.
  •   
  • SteadyMed Raises $12.2M to Advance PAH Therapy
  • (Pulmonary Hypertension News) Specialty pharmaceutical company SteadyMed Ltd. recently raised $12.2 million in equity financing, co-led by subsidiaries of Federated Investors Inc. and Deerfield Management Company L.P., as well as existing shareholders from the company. The funding will be invested in SteadyMed’s therapeutic product candidates for the treatment of orphan diseases, including pulmonary arterial hypertension (PAH).
  •   
  • February 28, 2015
  • CDC Says Influenza Vaccine Only 18% Effective This Year
  • (Medscape) The influenza vaccine this season has had little to no efficacy, in particular against the predominant A strains that have been circulating, said researchers from the Centers for Disease Control and Prevention (CDC) today.
  •   
  • Adempas Approved in Japan for the Treatment of Pulmonary Arterial Hypertension
  • (Financial) Following the approval of Adempas in January 2014 for the treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent or recurrent CTEPH after surgery, Adempas is now the first drug approved in Japan to treat two forms of pulmonary hypertension (PH). The development and commercialization of riociguat is part of the worldwide strategic collaboration with Merck (through a subsidiary) in the field of soluble guanylate cyclase (sGC) modulation. Merck is known as MSD outside of the U.S. and Canada.
  •   
  • February 26, 2015
  • Pregnancy in PAH Patients Focus of Recent Study
  • (Pulmonary Hypertension News) Pregnancy in women with pulmonary vasculopathies is rare with an incidence estimated at 1.1 per 100,000 pregnancies. There are a number of physiological changes that occur during pregnancy within the pulmonary and cardiovascular systems that create an increased synergistic stress, further aggravating PAH, which may lead to maternal and fetal demise.
  •   
  • February 25, 2015
  • PH Patients Given Higher Lung Transplant Priority with Revised LAS
  • (Pulmonary Hypertension News) Patients with pulmonary hypertension who require a lung transplant are expected to move to higher priority on the wait list for a life-saving organ. On February 19, the Lung Allocation System, which is a means of prioritizing patients in need of a lung transplant, was modified to accommodate a  number of policy changes that occurred over the course of many years.
  •   
  • February 24, 2015
  • Ultrasound-accelerated thrombolysis may improve pulmonary embolism outcomes
  • (2Minute Medicine) In patients with acute submassive pulmonary embolism (PE), ultrasound-accelerated catheter-directed thrombolysis (USAT) safely and effectively improved right ventricular (RV) dysfunction.
  •   
  • February 23, 2015
  • CTEPH Patients Are More Accurately Assessed During Exercise, Study Shows
  • (Lung Disease News) A team of researchers led Dr. Guido Claessen at the University Hospitals Leuven in Belgium recently published in the journal Heart their findings concerning the evaluation of chronic thromboembolic pulmonary hypertension (CTEPH) during exercise and the effects of administering sildenafil. The study is entitled “Exercise pathophysiology and sildenafil effects in chronic thromboembolic pulmonary hypertension.”
  •   
  • February 22, 2015
  • Treating pulmonary hypertension in pediatrics.
  • (PubMed) Pulmonary hypertension is a hemodynamic condition occurring rarely in pediatrics. Nevertheless, it is associated with significant morbidity and mortality. When characterized by progressive pulmonary vascular structural changes, the disease is called pulmonary arterial hypertension (PAH). It results in increased pulmonary vascular resistance and eventual right ventricular failure. In the vast majority of cases, pediatric PAH is idiopathic or associated with congenital heart disease, and, contrary to adult PAH, is rarely associated with connective tissue, portal hypertension, HIV infection or thromboembolic disease. Areas covered: This article reviews the current drug therapies available for the management of pediatric PAH. These treatments target the recognized pathophysiological pathways of PAH with endothelin-1 receptor antagonists, prostacyclin analogs and PDE type 5 inhibitors. New treatments and explored pathways are briefly discussed.
  •   
  • Ongoing Clinical Trial: Efficacy of Bosentan in Exercise-Induced PAH Secondary to Congenital Heart Disease
  • (Pulmonary Hypertension News) Earlier in the week, Pulmonary Hypertension News reported on how the drug Bosentan improved Pulmonary Hypertension Secondary to IPF in an individual case study. In a related story, medical researchers from the Academic Medical Center in Amsterdam, Netherlands, are currently recruiting adult patients (>18) with congenital heart disease for a clinical trial that aims to identify congenital heart disease patients with exercise-induced pulmonary arterial hypertension. Importantly, this study will analyze whether Bosentan is an effective treatment for these patients.
  •   
  • February 21, 2015
  • Up-regulation of Hexokinase1 in the Right Ventricle of Monocrotaline Induced Pulmonary Hypertension
  • (Medscape) Pulmonary arterial hypertension (PAH) is a proliferative arteriopathy associated with a glycolytic shift during heart metabolism. An increase in glycolytic metabolism can be detected in the right ventricle during PAH. Expression levels of glycolysis genes in the right ventricle during glycolysis that occur in monocrotaline (MCT)-induced pulmonary hypertension (PH) remain unknown.
  •   
  • Radionuclide angiography-assessed RVEF predicts PAH outcomes
  • (News Medical) Baseline right ventricular ejection fraction (RVEF) as evaluated by conventional planar equilibrium radionuclide angiography (ERNA) is significantly associated with outcomes in patients with pulmonary arterial hypertension (PAH), research suggests.
  •   
  • February 20, 2015
  • Recent IPF Study Addresses Emotional and Physical Impact on Both Patients and Caregivers
  • (Pulmonary Hypertension News) Results of a new study are shedding light on the emotional and physical impact that IPF has on both patients and caregivers. The new insights could help pave the way for improved patient care, leading to better quality of life for those with the disease.
  •   
  • February 19, 2015
  • Right Ventricular Remodeling Might be Adaptative in Idiopathic Pulmonary Arterial Hypertension
  • (Pulmonary Hypertension News) Researchers at the School of Medicine at Sapienza University of Rome found that Concentric hypertrophy in the heart right ventricle might represent a favorable adaptive pattern to increased afterload in idiopathic pulmonary arterial hypertension. The study, entitled “Right ventricular remodeling in idiopathic pulmonary arterial hypertension: adaptive versus maladaptive morphology,” was recently published in the Journal of Heart and Lung Transplantation.
  •   
  • February 18, 2015
  • Effects of chrysin (5,7-dihydroxyflavone) on vascular remodeling in hypoxia-induced pulmonary hypertension
  • (7Th Space) Chrysin (5,7-dihydroxyflavone) inhibits platelet-derived growth factor-induced vascular smooth muscle cell proliferation and arterial intima hyperplasia. This study aims to investigate the effects of chrysin on rat pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension (PH).
  •   
  • February 17, 2015
  • The Lasting Legacy of Fen-Phen
  • (Lawyers and Settlements) Los Angeles, CA: Ask anyone who was at all concerned about their weight in the mid-to-late ’90s and they’ll likely remember the fen-phen debacle: A weight loss drug that came with an increased risk of serious heart and lung problems. Those problems - primary pulmonary hypertension (now called pulmonary atrial hypertension) and/or heart valve problems - were the basis of many a fen-phen lawsuit. Thanks to those problems, diet drugs today are looked at skeptically by everyone from patients to health care providers.
  •   
  • February 16, 2015
  • Researchers Study PAH in Rheumatoid Arthritis Versus Idiopathic PAH
  • (Pulmonary Hypertension News) A new study out of Toronto, Canada has evaluated whether rheumatoid arthritis-associated pulmonary arterial hypertension (RA-PAH) is a more severe disease compared to idiopathic pulmonary arterial hypertension (IPAH). Published on January 13, 2015, the study is titled “Survival in rheumatoid arthritis-associated pulmonary arterial hypertension compared with idiopathic pulmonary arterial hypertension” and appeared in the journal Respirology.
  •   
  • Smoking is even MORE dangerous than we thought
  • (Deily Mail) New study links smoking to 26 diseases - five more than thought in past.
  •   
  • February 15, 2015
  • Bosentan Improves Pulmonary Hypertension Secondary to IPF in Individual Case Study
  • (Pulmonary Hypertension News) A study published in the journal Respiratory Medicine Case Reports revealed a case where a patient with idiopathic pulmonary fibrosis (IPF) was successfully treated for severe pulmonary hypertension (PH) with bosentan. The study is entitled “Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis.”
  •   
  • Native T1 myocardial tissue characterisation in patients with pulmonary hypertension: findings from International T1 Multicentre Study
  • (Paperity) Pulmonary hypertension is a severe disorder characterized by elevated pulmonary artery pressure leading to right ventricular (RV) failure and premature death. We have recently shown that high signal in septal myocardium by cardiovascular magnetic resonance (CMR) late gadolinium enhancement (LGE) imaging indicates more severe disease. This study investigated whether markers of interstitial septal changes by T1 mapping relate to parameters of biventricular function and structure and makers of disease severity in pulmonary hypertension.
  •   
  • February 14, 2015
  • EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-?1 signaling
  • (The Journal of Clinical Investigation) Pulmonary arterial hypertension (PAH) is commonly associated with chronic hypoxemia in disorders such as chronic obstructive pulmonary disease (COPD). Prostacyclin analogs are widely used in the management of PAH patients; however, clinical efficacy and long-term tolerability of some prostacyclin analogs may be compromised by concomitant activation of the E-prostanoid 3 (EP3) receptor. Here, we found that EP3 expression is upregulated in pulmonary arterial smooth muscle cells (PASMCs) and human distal pulmonary arteries (PAs) in response to hypoxia.
  •   
  • Pulmonary Arterial Hypertension Could Improve with Calorie Restriction
  • (Pulmonary Hypertension News) Calorie restriction has been recently popular as a way to stave off the aging process. Could this technique be effective for improving a disease, such as pulmonary arterial hypertension (PAH)? Researchers at Central Hospital in Xi’an China seem to think so. A recent report published in the Journal of Cardiovascular Pharmacology, titled Calorie Restriction Attenuates Monocrotaline-induced Pulmonary Arterial Hypertension in Rats, showed that caloric restriction in rats improved symptoms of PAH in the animals. The study appeared in the journal on January 29, 2015.
  •   
  • February 13, 2015
  • Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension
  • (American Heart Assc) Conclusions—EndoMT is linked to alterations in BPMR2 signaling and is involved in the occlusive vascular remodeling of PAH, which findings may have therapeutic implications.
  •   
  • February 12, 2015
  • Survival in rheumatoid arthritis-associated pulmonary arterial hypertension
  • (Wiley) Conclusions

    Compared with IPAH patients, RA-PAH patients have an older age of onset and lower baseline mPAP. RA-PAH patients have comparable survival to IPAH patients.
  •   
  • February 11, 2015
  • Suppression of the TRPC1 Gene Could Prevent Hypoxia-induced Pulmonary Hypertension
  • (PulmonaryHyperTensionNews) A team of researchers from Taiwan sought to understand if, by suppressing a gene called TRPC, they could prevent hypoxia-induced pulmonary hypertension (PAH)
    Findings from this study confirmed that RVSP and the expressions of TRPCs were significantly enhanced in a murine model of hypoxia-induced PAH and were markedly suppressed after siRNA-TRPC1 treatment. The authors’ concluded that these findings may offer a therapeutic option for the treatment of patients with PAH refractory to conventional regimens.
  •   
  • February 10, 2015
  • ERS Pulmonary Hypertension Research Award
  • (Bayer) Nominations for active research projects in the pulmonary hypertension field
  •   
  • February 9, 2015
  • Overview of pulmonary hypertension in adults
  • (UpToDate.com) A good source for PAH overview
  •   
  • Increasing Number of Promising PAH Drug Targets Are On the Horizon, According to Study
  • (Pulmonary Hypertension News) A group of pulmonary medical specialists from the University of South Paris School of Medicine (USPSM) in France have conducted a robust review study that examines the increasing number of potential novel therapeutic drug targets for patients with pulmonary arterial hypertension (PAH).  The study team, led by Dr. Marc Humbert, MD PhD, Professor of Respiratory Medicine, National Reference Centre for Pulmonary Hypertension at the Department of Respiratory and Intensive Care Medicine USPSM, published their findings in the latest edition of CHEST – a Journal of the American College of Chest Physicians.
  •   
  • February 8, 2015
  • SteadyMed Raises $12.2 Million To Advance PAH Therapy
  • (Pulmonary Hypertension News) SteadyMed Ltd., an Israel-based pharmaceutical company developing and commercializing therapeutic candidates to address the limitations of top market products in treating orphan diseases, recently announced that it raised $12.2 million in equity financing to fund its PAH drug development efforts. The financing round was led by subsidiaries of Deerfield Management Company L.P. and Federated Investors Inc. SteadyMed’s largest shareholders were also part of the financing.
  •   
  • West Michigan woman first in world to get life-saving heart device
  • (MLive) A West Michigan woman with heart disease became the first in the world to receive a new life-saving medical device, thanks to a “full court press” by Spectrum Health to get permission from federal regulators.
  •   
  • February 7, 2015
  • Bellerophon Therapeutics (BLPH) Plans to Raise $60 Million in February 13th IPO
  • (Ticker Report) Bellerophon Therapeutics provided the following description of their company for its IPO: “We are a clinical-stage therapeutics company focused on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. We have two programs in advanced clinical development. The first program, INOpulse, is based on our proprietary pulsatile nitric oxide delivery device. We are currently developing two product candidates under our INOpulse program: one for the treatment of pulmonary arterial hypertension, or PAH, for which we intend to commence Phase 3 clinical trials in the second half of 2015, and the other for the treatment of pulmonary hypertension ...
  •   
  • Networks Reveal the Connections of Disease
  • (Quanta Magazine) Stefan Thurner is a physicist, not a biologist. But not long ago, the Austrian national health insurance clearinghouse asked Thurner and his colleagues at the Medical University of Vienna to examine some data for them. The data, it turned out, were the anonymized medical claims records — every diagnosis made, every treatment given — of most of the nation, which numbers some 8 million people. The question was whether the same standard of care could continue if, as had recently happened in Greece, a third of the funding evaporated. But Thurner thought there were other, deeper questions that the data could answer as well.
  •   
  • February 6, 2015
  • Researchers Find That Physical Examination is Unreliable in Detecting Pulmonary Hypertension
  • (Pulmonary Hypertension News) A recent systematic review conducted by a research team from the University of Toronto in Canada sought to present the current state of agreement regarding the appropriate physical examination necessary for diagnosis of pulmonary hypertension (PH). The review, entitled “Utility of the Physical Examination in Detecting Pulmonary Hypertension. A Mixed Methods Study,” was published in the journal PLOS One.
  •   
  • February 5, 2015
  • Survival advantages of excess body mass index in patients with idiopathic pulmonary arterial hypertension.
  • We analysed 173 patients with IPAH. The patients were subclassified into categories of BMI defined as: under-weight (< 18.5 kg/m2), normal weight (18.5 to 24.9 kg/m2), overweight and obese (25 to 34.9 kg/m2). The three BMI groups had similar profiles in terms of haemodynamic parameters assessed by right heart catheterization and level of NT-proBNP.

    The Kaplan-Meier survival curves for the three BMI categories demonstrated that the overweight and obese group had a significantly higher survival rate than the normal weight and underweight groups (log-rank test, P = 0.027, P = 0.000, respectively). In a stepwise forward regression, lower BMI, higher WHO functional class, lower cardiac index, smaller LVEDDs and absence of targeted medication remained independent predictors of mortality.
  •   
  • February 4, 2015
  • New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication.
  • (CHEST) This review examines the state-of-the-art potential new targets for innovative research in PAH, focusing on (1) the crosstalk between cells within the pulmonary vascular wall, with particular attention to the role played by dysfunctional endothelial cells; (2) aberrant inflammatory and immune responses; (3) the abnormal extracellular matrix function; and (4) altered BMPRII/KCNK3 signaling systems. A better understanding of novel pathways and therapeutic targets will help in the designing of new and more effective approaches for PAH treatment.
  •   
  • February 3, 2015
  • SSc-PH May Show Increase in Damaged Blood Vessel Biomarker EMPs
  • (Pulmonary Hypertension News) Tiny biomarkers for pulmonary hypertension in patients with systemic sclerosis (SSc) may be floating around affected individuals’ bloodstreams. Matthew R. Lammi, MD, of Louisiana State University Health Sciences Center in New Orleans is heading a clinical trial to evaluate the presence of endothelial microparticles (EMPs) in SSc patients with or without pulmonary hypertension and compare the results between groups and against age-matched, healthy control participants.
  •   
  • Germany: Interview with a patient suffering from pulmonary arterial hypertension
  • (PVRI)
  •   
  • February 2, 2015
  • Calorie Restriction Attenuates Monocrotaline-induced Pulmonary Arterial Hypertension in Rats.
  • (Pubmed) The presented data demonstrateD that CR may serve as an effective treatment of PAH, and targeting the SIRT1/eNOS pathway may improve treatment of PAH.
  •   
  • February 1, 2015
  • Utility of the Physical Examination in Detecting Pulmonary Hypertension. A Mixed Methods Study
  • (Plos One) Patients with pulmonary hypertension (PH) often present with a variety of physical findings reflecting a volume or pressure overloaded right ventricle (RV). However, there is no consensus regarding the diagnostic utility of the physical examination in PH.
  •   
  • Early Treatment with Fumagillin, an Inhibitor of Methionine Aminopeptidase-2, Prevents Pulmonary Hypertension in Monocrotaline-Injured Rats
  • (Plos One) Pulmonary Hypertension (PH) is a pathophysiologic condition characterized by hypoxemia and right ventricular strain. Proliferation of fibroblasts, smooth muscle cells, and endothelial cells is central to the pathology of PH in animal models and in humans. Methionine aminopeptidase-2 (MetAP2) regulates proliferation in a variety of cell types including endothelial cells, smooth muscle cells, and fibroblasts. MetAP2 is inhibited irreversibly by the angiogenesis inhibitor fumagillin. We have previously found that inhibition of MetAP2 with fumagillin in bleomycin-injured mice decreased pulmonary fibrosis by selectively decreasing the proliferation of lung myofibroblasts. In this study, we investigated the role of fumagillin as a potential therapy in experimental PH.
  •   
  • Macrophage Activation May be the Cause of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
  • (Pulmonary Hypertension News) A team of Researchers led by Antje Prasse from the Department of Pneumology, University Medical Centre in Freiburg, Germany identified that macrophage activation and other cellular events may be part of the cause of acute exacerbations in idiopathic pulmonary fibrosis.
  •   
  • January 31, 2015
  • Don’t Neglect Your Pearly Whites
  • (Pulmonary Hypertension R.N.) Pulmonary arterial hypertension is not caused by dental problems but the resulting increased inflammation may amplify the disease. Regular dental check-ups are important to prevent abscessed teeth that can become very serious infections.  It is important to inform your dentist of your medical history (including pulmonary arterial hypertension) and any medications that you are taking. Some dentists will request a medical release form from your pulmonary hypertension physician prior to doing anything other than routine cleanings.
  •   
  • Treatment-related Biomarkers in Pulmonary Hypertension
  • (ATS Journals) Significant advances in the treatment of pulmonary arterial hypertension (PAH) over the last two decades have led to the introduction of multiple classes of oral therapy, but the disease remains devastating for many patients. Disease progression in spite of oral monotherapy is a major problem and alternative therapy, such as infusion of prostacyclins, is cumbersome and carries considerable potential morbidity. There is some evidence to support, and increasing use of, combination oral therapy including drugs from the endothelin receptor antagonist (ERA) and type-5 phosphodiesterase inhibitor (PDE5i) classes. Given the multiple but options thus available now in pulmonary hypertension (PH) therapy, biomarkers to guide treatment decisions could be helpful.
  •   

News Archives
Take the Current Poll
View Current Poll Results To Date
View the Poll Archives